SKIA_Breast, AR Navigation on Patient Body for Doctors Developed by SKIA Company

SKIA Co., Ltd. (CEO Lee Jong-Myung) has introduced an innovative technology that will lead to an evolution in surgical preparations and take procedures one step further.

SKIA_Breast is a digital surgery guide solution based on augmented reality (AR) that superimposes a patient’s medical images (like CT or MRI) with a real-time camera view of the surgeon. The surgeon can check the location or shape of tissue by examining an image which is projected onto the patient’s skin which could not normally be seen with the naked eye. Without having to visualize a two-dimensional image on the monitor as three-dimensional, the surgeon can concentrate more on the operation. Therefore, the accuracy and stability of the procedure are greatly improved.

For any successful surgery, it is very important to accurately capture the location and size of a lesion and to be able to reach the lesion by causing as little injury to the surrounding tissues as possible. This is one reason why a surgeon’s experience and the sensitivity and control in their fingertips have long been considered more important than anything else, despite the introduction of various cutting-edge diagnostic equipment or robots.

SKIA_Breast consists only of a tablet and a case with a 3D sensor, making it portable and easy to use. In addition, there is no need for a workstation with various sensors that are large and sensitive to shock or vibration.

SKIA_Breast can see through the human body, so it helps to reduce any deviation of skill level according to surgical experience. Additionally, for patients, radiation exposure from CT scans may be reduced. It can also replace wire localization, which is for patients with small lesions that cannot be identified by touch.

The biggest strength of the SKIA_Breast is that it is “markerless”. Most current AR technologies applied in surgery need multiple markers to be physically implanted in bone tissue such as the spine or skull. Since SKIA_Breast uses no markers, additional procedures to implant markers are not required. Moreover, through its further development, it can be used for education, patient explanation, and additional surgeries.

SKIA Co., Ltd. is a medical extended reality software development startup which was established on September 1, 2018. The company released a patent for a medical image augmented reality system in Korea in October 2019. Also in September 2020, they successfully registered a patent in the USA (US 10803608 B1). In October 2021, they won the Johnson & Johnson QuickFire Challenge 2021. Currently, SKIA_Breast is in a clinical trial phase with Ewha Womans University Hospital.

Lee Jong-Myung, the CEO of SKIA, said, “We are also working with other hospitals to expand application of our solution to procedures such as facial reconstruction and lithotripsy. In the future, we will develop a solution that can be applied to other organs such as liver and pancreas.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”